PCSK9 inhibitors are modern and effective hypolipidemic drugs for lowering LDL-cholesterol, which belong to the „biological therapy“. Their prescription is limited to specialized centers and to the fulfillment of other conditions set by SÚKL. This article lists the current valid criteria under which they can be indicated for reimbursement from public health insurance, and comments conditions and limitations in terms of the possibility of their fulfillment in clinical practice.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
pcsk9 inhibitors
8
[dyslipidemia pcsk9
4
inhibitors practical
4
practical focused
4
focused update
4
update indication
4
indication reimbursement
4
reimbursement criteria]
4
criteria] pcsk9
4
inhibitors modern
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!